THE ONLY ONCE-DAILY ORAL PARP INHIBITOR WITH PROVEN EFFICACY REGARDLESS OF BRCA STATUS1-4
ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3
The primary endpoint of the pivotal trial (NOVA), was progression-free survival (PFS) from time of randomization to time of disease progression or death. At the time of the PFS analysis, limited overall survival data were available, with 17% of survival events occurring in the study.1,4,5
Median PFS in the NOVA clinical trial:
BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.